B7-33 (6mg) Peptide – Research-Grade Relaxin Analog

B7-33 (6mg) is a synthetic peptide analog derived from the relaxin-2 hormone, engineered to selectively interact with the relaxin family peptide receptor 1 (RXFP1). Unlike full-length relaxin-2, B7-33 is a minimized peptide fragment designed to preserve receptor activation while offering improved stability and selectivity in experimental models. Because of these characteristics, B7-33 (6mg) has become an area of growing interest in fibrosis, cardiovascular, renal, and inflammatory pathway research.

At Core Peptide, we supply B7-33 (6mg) exclusively for research and laboratory use, supporting U.S.-based investigators with high-purity peptide compounds, transparent sourcing, and fast domestic fulfillment. Researchers exploring complementary signaling compounds may also review our broader Research Peptides Collection.

Scientific Overview of B7-33 (6mg)

B7-33 was developed as a biased agonist of the RXFP1 receptor. Native relaxin-2 activates multiple intracellular signaling pathways, some of which are associated with unwanted systemic effects in experimental settings. B7-33 was engineered to preferentially activate anti-fibrotic and cytoprotective signaling cascades while minimizing pathways associated with vasodilatory or hormonal side effects.

Due to this signaling bias, B7-33 (6mg) is frequently studied as a tool peptide for understanding how RXFP1 activation influences extracellular matrix remodeling, collagen deposition, and tissue elasticity.

Mechanism of Action (Research Hypothesis)

Researchers hypothesize that B7-33 (6mg) binds selectively to the RXFP1 receptor and initiates downstream intracellular signaling without fully replicating the complete signaling profile of endogenous relaxin-2.

Proposed mechanisms include:

• Activation of RXFP1-associated G-protein pathways

• Modulation of ERK1/2 and cAMP signaling

• Downregulation of TGF-β–mediated fibrotic pathways

• Reduced collagen synthesis and fibroblast activation

• Promotion of tissue remodeling and elasticity in experimental models

This selective signaling behavior has made B7-33 (6mg) particularly valuable in fibrosis research, where excessive extracellular matrix deposition is a defining characteristic.

Chemical Characteristics of B7-33 (6mg)

• Peptide Class: Relaxin-2 analog

• Target Receptor: RXFP1

• Form: Lyophilized powder

• Purity: Research-grade

• Intended Use: Laboratory and scientific research only

For molecular and structural reference data, researchers may consult peer-reviewed summaries available through the National Center for Biotechnology Information (NCBI) and related peptide chemistry databases.

Research Areas Involving B7-33 (6mg)

Fibrosis Research Models

One of the most prominent research applications of B7-33 (6mg) is in organ fibrosis models, including cardiac, renal, pulmonary, and hepatic fibrosis. Studies suggest that selective RXFP1 activation may reduce fibroblast proliferation and suppress excessive collagen accumulation, making B7-33 a valuable comparator peptide in anti-fibrotic pathway investigations.

Cardiovascular Research

RXFP1 signaling has been implicated in vascular compliance and myocardial remodeling. Experimental data indicate that B7-33 may preserve beneficial relaxin-mediated effects on cardiac tissue without triggering broader systemic vasodilation. As a result, B7-33 (6mg) is frequently included in cardiovascular signaling and myocardial injury research.

Renal Function Studies

Preclinical research has explored the role of RXFP1 activation in renal perfusion and structural remodeling. B7-33 is often studied in kidney disease models to evaluate whether selective relaxin signaling may influence fibrosis progression and renal tissue integrity.

Inflammatory Pathway Research

Researchers have also examined whether B7-33 (6mg) indirectly modulates inflammatory mediators by altering fibroblast and immune cell interactions. This makes the peptide relevant in studies investigating chronic inflammation and tissue repair dynamics.

Comparative Relaxin Research

Because B7-33 is a truncated relaxin analog, it is frequently used alongside native relaxin-2 to compare full agonist vs biased agonist receptor responses. These comparisons help clarify which intracellular pathways are most critical for anti-fibrotic and cytoprotective effects.

How B7-33 (6mg) Fits Within Peptide Research

In peptide research catalogs, B7-33 (6mg) is often grouped with compounds targeting growth factors, cytokines, and tissue-regulating hormones. While it is mechanistically distinct from growth hormone–related peptides such as Sermorelin & GHRP-2 Blend, researchers may study these compounds in parallel when evaluating systemic signaling, tissue repair, and anabolic vs anti-fibrotic responses.

Why Order B7-33 (6mg) from Core Peptide?

• U.S.-based peptide supplier

• High-purity research-grade compounds

• Fast shipping within the United States

• Clear documentation and labeling

• Strict research-only compliance

Explore additional experimental compounds in our Core Peptide catalog to support multi-pathway research designs.

External Scientific References

• National Center for Biotechnology Information (NCBI) – Relaxin and RXFP1 signaling

• PubMed – B7-33 and biased agonism studies

• Nature Reviews Endocrinology – Relaxin peptide signaling pathways

• Journal of Molecular Endocrinology – Fibrosis and RXFP1 modulation research